Drugs / MF59C.1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01376726 Background | Jul 2011 → Dec 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF59C.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01376726 ↗ |
| Route | Intramuscular | “Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.” NCT01376726 ↗ |